Wellington Management Group LLP Decreases Stake in Ultragenyx Pharmaceutical Inc. $RARE

Wellington Management Group LLP decreased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 52.6% in the second quarter, HoldingsChannel.com reports. The fund owned 1,250,464 shares of the biopharmaceutical company’s stock after selling 1,390,348 shares during the period. Wellington Management Group LLP’s holdings in Ultragenyx Pharmaceutical were worth $41,753,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in RARE. CANADA LIFE ASSURANCE Co boosted its stake in Ultragenyx Pharmaceutical by 2.0% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 26,932 shares of the biopharmaceutical company’s stock worth $817,000 after purchasing an additional 534 shares during the last quarter. Van ECK Associates Corp boosted its position in Ultragenyx Pharmaceutical by 26.1% during the third quarter. Van ECK Associates Corp now owns 2,650 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 549 shares during the last quarter. Tidal Investments LLC raised its holdings in Ultragenyx Pharmaceutical by 4.7% in the 2nd quarter. Tidal Investments LLC now owns 12,591 shares of the biopharmaceutical company’s stock valued at $458,000 after acquiring an additional 564 shares during the last quarter. Rafferty Asset Management LLC lifted its stake in Ultragenyx Pharmaceutical by 0.4% in the 4th quarter. Rafferty Asset Management LLC now owns 157,061 shares of the biopharmaceutical company’s stock worth $3,612,000 after purchasing an additional 577 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 43.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 751 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RARE has been the topic of a number of analyst reports. JPMorgan Chase & Co. downgraded Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $80.00 to $36.00 in a research report on Thursday. William Blair cut shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Thursday. Evercore cut shares of Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price objective for the company. in a research report on Thursday. Royal Bank Of Canada lifted their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $37.53.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Several analysts still see potential value in Ultragenyx’s commercial rare-disease portfolio. Wall Street firms including Jefferies, Citi, TD Cowen, Canaccord Genuity, Cantor Fitzgerald and HC Wainwright retained positive ratings, although they materially reduced their price targets. Ultragenyx Stock Sinks on Drug Trial Failure
• Positive Sentiment: Unusually heavy call-option activity and speculation that Ultragenyx could become a takeover target—potentially for another rare-disease company such as BioMarin—provided limited support for a possible rebound, though neither represents a company-confirmed development. Ultragenyx Could Be M&A Target
• Neutral Sentiment: Management is expected to evaluate “significant” cost reductions and reconsider the future of the Angelman program. Investors will also focus on the company’s existing commercial products and any updated strategic plans. Ultragenyx to Weigh Cost Cuts
• Negative Sentiment: The ASPIRE study failed to meet both its primary endpoint—change in Bayley-4 cognitive raw score—and key secondary endpoint, net response on the Multidomain Responder Index. The results substantially weaken the outlook for apazunersen and remove a major potential source of future revenue. Ultragenyx Announces Phase 3 ASPIRE Results
• Negative Sentiment: The trial failure triggered multiple downgrades and steep price-target cuts. Wells Fargo moved to equal weight, Bank of America cut its rating to neutral, and firms including Baird, JPMorgan, Evercore and others lowered targets, reflecting higher clinical, commercial and valuation risk. Ultragenyx Shares Crater After Trial Failure

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Parschauer sold 1,899 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the transaction, the executive vice president owned 94,462 shares in the company, valued at $2,325,654.44. The trade was a 1.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Corsee Sanders sold 2,000 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the sale, the director owned 21,095 shares in the company, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $14.85 on Friday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $13.81 and a 1-year high of $39.89. The firm has a market cap of $1.46 billion, a PE ratio of -2.54 and a beta of 0.31. The company has a 50-day moving average of $28.07 and a two-hundred day moving average of $25.04.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The firm had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. During the same quarter in the previous year, the business earned ($1.17) EPS. The company’s quarterly revenue was up 28.5% compared to the same quarter last year. Sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -3.97 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.